Paid Clinical Trials District of Columbia

Discover 802 paid clinical trials in District of Columbia. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 802

Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting

PHASE2

Sponsor:

Allogene Therapeutics

Location:

Washington DC, Fairfax VA, Newark DE, Charlottesville VAshow 33 more

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

PembrolizumabLong-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Washington DC, Columbia MD, Baltimore MD, Richmond VAshow 68 more

Code:

NCT03486873

Conditions

Solid Tumors

Hematologic Malignancies

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Standard of Care (SOC)

Lenvatinib

Olaparib

MK-4280

CrizanlizumabA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Washington DC, Bronx NY, Greenville NC, Augusta GAshow 3 more

Code:

NCT06439082

Conditions

Sickle Cell Disease

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Crizanlizumab

Placebo

BXCL701 & PembrolizumabBXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting

PHASE2

Sponsor:

Georgetown University

Location:

Washington DC, Hackensack NJ

Code:

NCT05558982

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BXCL701

Pembrolizumab

Observational StudyNational Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Recruiting

Sponsor:

Children's Hospital Medical Center, Cincinnati

Location:

Washington DC, Falls Church VA, Baltimore MD, Harrisburg PAshow 53 more

Code:

NCT02852031

Conditions

Hypoplastic Left Heart Syndrome (HLHS)

Eligibility Criteria

Sex: All

Age: 0 - 15

Healthy Volunteers: Not accepted

Interventions

Collaborative Learning Network

SurVaxMA Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Recruiting

PHASE1

Sponsor:

Pediatric Brain Tumor Consortium

Location:

Washington DC, Pittsburgh PA, New York NY, Buffalo NYshow 10 more

Code:

NCT04978727

Conditions

Medulloblastoma

Glioblastoma Multiforme

Anaplastic Astrocytoma

High-grade Astrocytoma NOS

Anaplastic Oligodendroglioma

Eligibility Criteria

Sex: All

Age: 1 - 21

Healthy Volunteers: Not accepted

Interventions

SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years

SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years

SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years

SEVENFACT®SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Recruiting

Sponsor:

American Thrombosis and Hemostasis Network

Location:

Washington DC, New Hyde Park NY, Greenville NC, Cleveland OHshow 17 more

Code:

NCT04647227

Conditions

Hemophilia A With Inhibitor

Hemophilia B With Inhibitor

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

coagulation factor VIIa [recombinant]-jncw

ObeldesivirStudy of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection

Recruiting

PHASE2

Sponsor:

Gilead Sciences

Location:

Washington DC, Pittsburgh PA, Syracuse NY, Union City GAshow 30 more

Code:

NCT06784973

Conditions

RSV Infection

Eligibility Criteria

Sex: All

Age: 0 - 5

Healthy Volunteers: Not accepted

Interventions

Obeldesivir

Obeldesivir Placebo

ParicalcitolA Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Washington DC, Philadelphia PA, Winston-Salem NC, Charlotte NCshow 8 more

Code:

NCT04064827

Conditions

Chronic Kidney Disease (CKD)

Secondary Hyperparathyroidism (SHPT)

Eligibility Criteria

Sex: All

Age: 0 - 9

Healthy Volunteers: Not accepted

Interventions

Paricalcitol

FF-10832 & PembrolizumabA Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Recruiting

PHASE2

Sponsor:

Fujifilm Pharmaceuticals U.S.A., Inc.

Location:

Washington DC, Fairfax VA, Philadelphia PA, Morristown NJshow 18 more

Code:

NCT05318573

Conditions

Advanced Urothelial Carcinoma

Advanced Non Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

FF-10832

Popular cities in District of Columbia

Washington, D.C.